Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention

Current Medical Research and Opinion

Volumn 25, Issue 11, 2009, Pages 2795-2804

  Stewart, Dan L ^a   Romero, José R ^b   Buysman, Erin K ^c   Fernandes, Ancilla W ^d   Mahadevia, Parthiv J ^d  

^a UNIVERSITY OF LOUISVILLE HOSPITAL   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c i3 Innovus   (United States)

^d MEDIMMUNE   (United States)

Author keywords

Healthcare costs; Lower respiratory infection; Preterm infants; Respiratory syncytial virus

Indexed keywords

ARTICLE; BIRTH WEIGHT; CHILD HOSPITALIZATION; EMERGENCY WARD; FEMALE; GESTATIONAL AGE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INFANT; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PREMATURITY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RNA VIRUS INFECTION; UNITED STATES;

ALGORITHMS; CASE-CONTROL STUDIES; COHORT STUDIES; HEALTH CARE COSTS; HEALTH RESOURCES; HOSPITALIZATION; HUMANS; INFANT; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE; MANAGED CARE PROGRAMS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 72549097489     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903290894     Document Type: Article

References (34)

1. Institute of Medicine. Prospects for immunizing against respiratory syncytial virus. In: New vaccine development: establishing priorities: volume 1, diseases of importance in the United States. Washington, DC: National Academy Press, 1985:397-409
2. Hall CB. Respiratory syncytial virus. In: Feigen RD, Cherry JD, eds. Textbook of Pediatric Infectious Diseases. Philadelphia, PA: WB Saunders, 1987:1653-1675
3. Hall C. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001;344:1917-1928
4. Ruuskanen O, Ogra PL. Respiratory syncytial virus. Curr Probl Pediatr 1993;23:50-79
5. Shay DK, Holman RC, Newman RR, et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999;282:1440-1446
6. Prober CG, Wang EE. Reducing the morbidity of lower respiratory tract infections caused by respiratory syncytial virus: still no answer. Pediatrics 1997;99:472-475
7. McLaurin KK, Leader S. Growing impact of RSV hospitalizations among infants in the US, 1997-2002. Presented at the Pediatric Academic Societies Annual Meeting; 14-17 May 2005; Washington, DC. Abstract 936
8. Law BJ, Carbonell-Estrany X, Simoes EA. An update on respiratory syncytial virus epidemiology: a developed country perspective. Respir Med 2002;96(Suppl B):S1-7 (Pubitemid 39665384)
9. American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, Baker CJ, Long SS, et al., eds. Red Book: 2006 report of the Committee on Infectious Diseases. 27th rev edn. Elk Grove Village, IL: American Academy of Pediatrics, 2006:560-567
10. Oelberg D, Reininger M, Eeckhout JV. A cost-benefit analysis of respiratory syncytial virus hyperimmune globulin (RSV-IVIG) in high-risk infants. Neonatal Intensive Care 1998;11:29-33
11. Katz BZ, Lo J, Sorrentino M. Costs of respiratory syncytial virus infection at a tertiary-care children's hospital. Pharmacol Ther 2003;28:343-345 (Pubitemid 37499093)
12. Altman CA, Englund JA, Demmler G, et al. Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening. Pediatr Cardiol 2000;21:433-438 (Pubitemid 30676877)
13. Howard TS, Hoffman LH, Stang PE, et al. Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality. J Pediatr 2000;137:227-232
14. Kohlhase K, Leader S. Impact of congenital heart disease (CHD) on RSV hospital resource use. Pediatr Res 2003;53(4[Part 2 of 2]):486A. Abstract 2743
15. Ehlken B, Ihorst G, Lippert B, et al. Economic impact of community-acquired and nosocomial lower respiratory tract infections in young children in Germany. Eur J Pediatr 2005;164:607-615 (Pubitemid 41428246)
16. Roeckl-Wiedmann I, Liese JG, Grill E, et al. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003;162:237-244 (Pubitemid 36437756)
17. Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child 2003;88:1065-1069 (Pubitemid 38064480)
18. Miedema CJ, Kors AW, Tjon A, et al. Medical consumption and socioeconomic effects of infection with respiratory syncytial virus in the Netherlands. Pediatr Infect Dis J 2001;20:160-163 (Pubitemid 32151938)
19. Rietveld E, De Jonge HC, Polder JJ, et al. Anticipated costs of hospitalization for respiratory syncytial virus infection in young children at risk. Pediatr Infect Dis J 2004;23:523-529 (Pubitemid 38802297)
20. Langley JM, Wang EE, Law BJ, et al. Economic evaluation of respiratory syncytial virus infection in Canadian children: a Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. J Pediatr 1997;131(1 Pt 1):113-117 (Pubitemid 27498318)
21. Joffe S, Ray GT, Escobar GJ, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999;104(3 Pt 3):419-427 (Pubitemid 29424659)
22. Stevens TP, Sinkin RA, Hall CB, et al. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med 2000;154:55-61 (Pubitemid 30027656)
23. Elhassan NO, Sorbero ME, Hall CB, et al. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med 2006;160:1070-1076
24. Kamal-Bahl S, Doshi J, Campbell J. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. Arch Pediatr Adolesc Med 2002;156:1034-1041 (Pubitemid 36343482)
25. Nuijten MJ, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics 2007;25:55-71 (Pubitemid 46072368)
26. Lázaro y de Mercado P, Figueras Aloy J, Doménech Martínez E, et al. The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain [in Spanish]. An Pediatr (Barc) 2006;65:316-324
27. Sampalis J. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 2003;143(5 Suppl):S150-6 (Pubitemid 37456913)
28. Greenough A, Cox S, Alexander J, et al. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child 2001;85:463-468 (Pubitemid 33116475)
29. US Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Chained Consumer Price Index for all urban consumers (C-CPI-U) 1999-2008, Medical Care. Series ID: SUUR0000SAM. Washington, DC: US Dept. of Labor, Bureau of Labor Statistics, 2008. Available at: http://data.bls.gov/cgi-bin/surveymost? su [Last accessed 9 June 2008]
30. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ 1998;17:283-295
31. Carroll K, Gebretsadik T, Griffin MR, et al. Increasing burden and risk factors for bronchiolitis-related medical visits in infants enrolled in a state health care insurance plan. Pediatrics 2008;122:58-64
32. Broughton S, Sylvester KP, Fox G, et al. Lung function in prematurely born infants after viral lower respiratory tract infections. Pediatr Infect Dis J 2007;26:1019-1024 (Pubitemid 350287584)
33. Friedrich L, Stein RT, Pitrez PM, et al. Reduced lung function in health preterm infants in the first months of life. Am J Respir Crit Care Med 2006;173:442-447 (Pubitemid 43228333)
34. Friedrich L, Pitrez PM, Stein RT, et al. Growth rate of lung function in healthy preterm infants. Am J Respir Crit Care Med 2007;176:1269-1273 (Pubitemid 350256481)